JNJ
Johnson & Johnson
NYSE · Healthcare · Drug Manufacturers - General · US
$276.58
−0.66%Year over year
Reported trailing growth
- Revenue
- +8.1%
- EBITDA
- -5.4%
- EBIT
- +18.1%
- EPS
- -8.1%
- Free cash flow
- +14.0%
- Operating cash flow
- +2.9%
Forward estimates
Based on analyst estimates
- Revenue
- +6.5%
- EBITDA
- +19.3%
- EPS
- +37.9%
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- +15.6%
- EBIT
- +6.8%
- Net income
- +14.3%
- EPS
- +17.3%
- Free cash flow
- +4.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026